紫杉醇和顺铂加放疗同步治疗Ⅲ期非小细胞肺癌临床观察  

A clinical trial of combination of paclitaxel with cisplatin and synchronous radiotherapy in treatment of patients with stage-Ⅲ non-small-cell lung cancer

作　　者：杨新华[1] 钟兰俊[1] 李延持[1] 沙江[1] 袁双虎[1] 

机构地区：[1]山东省肿瘤医院放疗科,济南250117

出　　处：《中国肿瘤临床与康复》2005年第2期163-165,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察同步放化疗治疗局部晚期非小细胞肺癌的近期疗效和急性毒副反应。方法40例Ⅲ期非小细胞肺癌患者放疗前1周开始化疗,采用每4周休2周方案,紫杉醇80mg m2溶于生理盐水500ml中,第1,8,29,36天给药;顺铂20mg m2,第2～6和30～35天;常规放疗2Gy次,1次d,5d周,肿瘤灶总剂量66Gy7周。结果近期疗效:完全缓解(CR)率为30.0%,部分缓解(PR)率为57.5%,总有效率87.5%。主要毒副反应是急性放射性食管炎和肺炎,放射性食管炎的发生率为52.5%,放射性肺炎为37.5%,但大多数患者经过对症支持治疗均能耐受。结论紫杉醇、顺铂加放疗同步治疗局部晚期非小细胞肺癌,近期疗效肯定,远期疗效和晚期并发症有待进一步观察。Objective To assess the immediate response and acute side effects of radiotherapy with concurrent chemotherapy in the treatment of stage-Ⅲ non-small cell lung cancer (NSCLC).Methods Forty patients with stage-Ⅲ NSCLC were treated with radiotherapy (2.0 Gy/f,5 times a week, to a total dose of 66 Gy/7 weeks) in combination with concurrent paclitaxel (80 mg/m^2 given intravenously on days 1,8,29 and 36) and cisplatin (20 mg/m^2 given intravenously on days 2-6 and 30-35) chemotherapy.Results The overall immediate response rate was 87.5%(CR+PR).According to the RTOG criterion system,acute radiation esophagitis occurred in 52.5% and acute radiation pneumonitis occurred in 37.5% of the patients.Conclusions Concurrent radiotherapy and chemotherapy can be considered as an effective and feasible approach for treatmont of NSCLC with good response and without any early serious complications. The long-term survival and specific injury should await further study.

关 键 词：肺肿瘤/放射疗法 肺肿瘤/化学疗法 

分 类 号：R734.2[医药卫生—肿瘤] R730.58[医药卫生—临床医学]